Indeed, in osteosarcoma TRIM22 induction and the consequent NRF2 ubiquitination have been found to reduce progression and metastasis, making TRIM22 a target and a viable option for a synergic therapeutic strategy when coupled with KEAP1 induction [59]. This evidence concerns the gene NFE2L2 and osteosarcoma.